ArticleSurgery today2012
Mediastinoscopy-assisted esophagectomy for esophageal cancer in patients with serious comorbidities.
Article in Surgery today, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparison of mediastinoscopy and thoracoscope minimally invasive esophagectomy in the treatment of esophageal cancer: a meta-analysis and system review.BMC cancer · 2025Pooled it
- Novel Mediastinoscope-Assisted Minimally Invasive Esophagectomy for Esophageal Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2023Pooled it
- Inflatable mediastinoscopic esophagectomy for refractory benign esophageal fistulas: An effective therapeutical methods.JTCVS techniques · 2026Article
- Single-port inflatable mediastinoscopy combined with laparoscopic esophagectomy via right cervical auxiliary operating port and sternal lifting: a safe and reliable surgical method.Journal of thoracic disease · 2025Article
- Application of Inflatable Video-Assisted Mediastinoscopic Transhiatal Esophagectomy in Individualized Treatment of Esophageal Cancer.Biomedicines · 2023Review
- Clinical-pathological features and perioperative outcomes of mediastinoscopy vs. thoracoscopy esophagectomy in esophageal cancer: A meta-analysis.Frontiers in surgery · 2023Review
- Sternal lifting increases the operating space in esophagectomy via mediastinoscopy: a prospective cohort study.Journal of thoracic disease · 2021Article
- The application of rigid and flexible mediastinoscopy in esophagectomy: our experience and a new technology.World journal of surgical oncology · 2021Article
- Mediastinoscopy-assisted transhiatal esophagectomy versus thoraco-laparoscopic esophagectomy for esophageal cancer: a single-center initial experience.Journal of thoracic disease · 2020Article
- Risk factors and measures of pulmonary complications after thoracoscopic esophagectomy for esophageal cancer.Surgery today · 2019Article
- Long-term outcomes of mediastinoscopic esophagectomy in early esophageal squamous cell carcinoma: 269 cases study.Mediastinum (Hong Kong, China) · 2019Article
- Mediastinoscopic esophagectomy for patients with early esophageal cancer.Journal of thoracic disease · 2015Article
- Risk factors for pulmonary complications after esophagectomy for esophageal cancer.Surgery today · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated the results of mediastinoscopy-assisted esophagectomy (MAE), performed for esophageal cancer patients with comorbidities, versus those of thoracoscopic esophagectomy (TSE), performed for esophageal patients with or without comorbidities.
methodsAmong 153 patients who underwent esophageal cancer surgery at our hospital, 17 (11.1%) underwent MAE and 37 (24.2%) underwent TSE.
resultsMany of the MAE group patients had pulmonary (P < 0.001), cardiovascular (P = 0.031), or hepatic (P = 0.0029) diseases preoperatively, and these comorbidities frequently overlapped (P < 0.0001). The %VC and FEV(1)/FVC were lower (P = 0.0099 and P = 0.0057, respectively), and the ICG-R15 and serum level of HbA1c were higher (P = 0.0014 and P = 0.043, respectively) in the MAE group. There were no differences in postoperative complications or in the modified Clavien classification between the groups. There was no mortality in either group. After MAE, 5 (29.4%) patients died of other diseases. The 5-year overall survival rate after MAE was poorer than that after TSE (56.1 vs. 71.8%), but the 5-year cause-specific survival rates were similar in the two groups.
conclusionsMAE is feasible for esophageal cancer patients with serious comorbidities and may decrease morbidity and mortality.
Indexed as
Identifiers
22068678What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.